Business Wire

MUNICH-RE

Share
Munich Re’s ALLFINANZ Spectra Turns Pre-Assessment Chaos into Instant Sales, STP and Analytics

Munich Re Automation Solutions Ltd, the global leader in digital new business and underwriting solutions, again disrupts life insurance automation by releasing ALLFINANZ Spectra. Cloud-based Spectra turns an inefficient pre-assessment process into closed sales. Spectra promotes the buying decision into the first two minutes of contact.

Agents or prospects enter minimal data and watch Spectra instantly assess insurability and probable pricing. Guided questions dynamically fine-tune results before their eyes and initiate the building blocks towards a formal application. At every point, the agent is empowered with adequate knowledge to suggest a close.

Today's impatient clients stay interested. Higher risks aren't mired in discouraging, sale-killing detours. All parties know in minutes who is insurable, in which rate categories, and who is not. Agents can use one request to query single or multiple insurers for multiple benefit types.

"The hard work that agents and underwriters put into pre-assessments is often wasted," says Colm Kennedy, Executive Vice President Americas at Munich Re Automation Solutions. "Requests often clog underwriters' desks with telephone notes or consume hours in emails. Conversion rates are abysmal at 4%. Resulting quick-quotes risk inconsistency because data from that phase never arrives into rules engines to inform the formal decisions."

"Spectra remedies these problems and can deploy worldwide to advisers and staff on every platform within days," Kennedy continues. Spectra's intuitive graphical display or spectrograph of underwriting outcomes immediately shows brokers and prospects their results as calculated by the insurer's underwriting rulebook. Similarly, rules engines assimilate and leverage previously wasted input and business intelligence from hundreds of pre-assessments per week.

Kennedy adds, "Sales forces and prospects benefit when Spectra suggests upsells, cross-sells, or down-sells. High-risk clients you might have lost—or income-guarantee sales you'd have missed—now augment agents' and insurers' bottom lines, while insurance for those who thought they were uninsurable becomes a possibility."

Underwriter bottlenecks dissolve, assessment consistency is achieved and distributors become informed. ALLFINANZ Spectra is a turnkey solution that requires no IT effort to implement and can be made available quickly to your entire distribution network.

"Every sale has an emotional component," says Kennedy. "Don't let interest cool—or let other agents interlope—while old procedures plod along."

Contact:

Munich Re Automation Solutions Ltd
David Bordas
Tel: +353 1 293 2888
dbordas@munichre.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press release

Collaboration to Deliver Safer, Smarter, and Cost-Effective Automation for Warehouses and Factories Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press release

Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biologyLead program ST-905, a potent M1/M4 muscarinic agonist, currently in Phase 1 clinical developmentSecond program ST-901, a novel NMDA antagonist, currently in IND-enabling studies and expected to enter Phase 1 development next yearSeries A co-led by Dexcel Pharma and Third Rock Ventures with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorder

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye